UK Markets closed
NIKKEI 225
28,871.78 +324.80 (+1.14%) HANG SENG
20,040.86 -134.76 (-0.67%) CRUDE OIL
88.63 -3.46 (-3.76%) GOLD FUTURES
1,794.70 -20.80 (-1.15%) DOW
33,882.69 +121.64 (+0.36%) BTC-GBP
20,091.36 -308.91 (-1.51%)
Gilead Sciences, Inc. (GILD)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 12:21PM EDT. Market open.
| Previous close | 62.96 |
| Open | 63.85 |
| Bid | 65.64 x 800 |
| Ask | 65.65 x 1100 |
| Day's range | 63.66 - 65.92 |
| 52-week range | 57.17 - 74.12 |
| Volume | |
| Avg. volume | 6,901,254 |
| Market cap | 82.281B |
| Beta (5Y monthly) | 0.39 |
| PE ratio (TTM) | 11.22 |
| EPS (TTM) | 5.84 |
| Earnings date | 27 Apr 2022 - 02 May 2022 |
| Forward dividend & yield | 2.92 (4.89%) |
| Ex-dividend date | 14 Jun 2022 |
| 1y target est | 69.48 |
- Editor's pickYahoo Finance Video
Stocks gaining in early trading: Nvidia, AMD, Tesla, Moderna, Gilead
Yahoo Finance Live’s Brad Smith breaks down how stocks are moving in early trading.
- Business Wire
Trodelvy® Significantly Improves Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in the TROPiCS-02 Study
FOSTER CITY, Calif., August 15, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced statistically significant and clinically meaningful results from the second interim analysis of the key secondary endpoint of overall survival (OS) in the Phase 3 TROPiCS-02 study evaluating Trodelvy® (sacituzumab govitecan-hziy) in patients with HR+/HER2- metastatic breast cancer who received prior endocrine therapy, CDK4/6 inhibitors and two to four lines of chemotherapy. Detailed OS results will be pres
- Motley Fool
3 Healthcare Stocks With High Profit Margins
If you want to invest in profitable healthcare companies in this bear market, these all look like good bets.
© 2022 Yahoo. All rights reserved.
